Last reviewed · How we verify
Capecitabine, Oxaliplatin, Cetuximab
Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells. Oxaliplatin is a platinum-based chemotherapy drug that works by cross-linking DNA in cancer cells, thereby inhibiting their replication. Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), blocking its activation and subsequent signaling pathways that promote cancer cell growth.
Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells. Oxaliplatin is a platinum-based chemotherapy drug that works by cross-linking DNA in cancer cells, thereby inhibiting their replication. Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), blocking its activation and subsequent signaling pathways that promote cancer cell growth. Used for Metastatic colorectal cancer, Advanced gastric cancer.
At a glance
| Generic name | Capecitabine, Oxaliplatin, Cetuximab |
|---|---|
| Also known as | xeloda, oxalitin, Erbitux |
| Sponsor | Asan Medical Center |
| Drug class | Antineoplastic agents |
| Target | EGFR, thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Capecitabine's mechanism of action is based on its conversion to 5-fluorouracil, which is a thymidylate synthase inhibitor. This inhibition disrupts DNA synthesis in cancer cells, ultimately leading to cell death. Oxaliplatin, on the other hand, works by forming platinum-DNA adducts that prevent DNA replication and transcription. Cetuximab's mechanism involves binding to the EGFR, preventing its activation and subsequent signaling pathways that promote cancer cell growth and survival.
Approved indications
- Metastatic colorectal cancer
- Advanced gastric cancer
Common side effects
- Diarrhea
- Neutropenia
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (PHASE4)
- Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis (PHASE2)
- A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (PHASE3)
- Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer (PHASE2)
- Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer (PHASE2)
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer (PHASE2)
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine, Oxaliplatin, Cetuximab CI brief — competitive landscape report
- Capecitabine, Oxaliplatin, Cetuximab updates RSS · CI watch RSS
- Asan Medical Center portfolio CI